Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 1087-1093

  Creemers, G J ^a   Gerrits, C J ^a   Eckardt, J R ^a   Schellens, J H ^a   Burris, H A ^a   Planting, A S ^a   Rodriguez, G I ^a   Loos, W J ^a   Hudson, I ^a   Broom, C ^a   Verweij, J ^a   Von Hoff, D D ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; TOPOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 0031056424     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.1087     Document Type: Article

References (19)

1. Kingsburry WD, Boehm JC, Jakas DR, et al: Synthesis of watersoluable (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 34:98-107, 1991
2. Hsiang YH, Hertzberg R, Hecut S, et al: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985
3. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
4. Houghton PJ, Cheshire PJ, Myers L, et al: Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin (topotecan) against xenografts derived from adult and childhood tumors. Cancer Chemother Pharmacol 31:229-239, 1992
5. Burris HA III, Hanauske AR, Johnson RK, et al: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units. J Natl Cancer Inst 84:1816-1820, 1992
6. Hochster H, Liebes L, Speyer J, et al: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 12:553-559, 1994
7. Creemers GJ, Schellens JHM, Beynen JH, et al: Bioavailability of oral topotecan, a new topoisomerase I inhibitor. Proc Am Soc Clin Oncol 13:132, 1994 (abstr)
8. Kuhn J, Rizzo J, Eckardt J, et al: Phase I bioavailability study of oral topotecan. Proc Am Soc Clin Oncol 14:474, 1995 (abstr)
9. Loos WJ, Stoter G, Verweij J, et al: Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and the lactone ring-opened product (hydroxy-acid) in human plasma and urine. J Chromatogr Biomed Appl 678:309-315, 1996
10. Holford NH, Sheiner LB: Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:242-247, 1981
11. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271-291, 1993
12. Creemers GJ, Lund B, Verweij J: Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 20:73-96, 1994
13. Rothenberg MC, Kuhn JG, Burris HA III, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
14. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonylcamptothecin (CPT) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427-436, 1994
15. Catimel G, Chabot GG, Guastalla JP, et al: Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 6:133-140, 1995
16. Abigerges D, Chabot GG, Armand JP, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995
17. Creemers GJ, Schellens JHM, Planting AST, et al: Cumulative myelosuppression of topotecan (T) administered as a 21-days continuous infusion in patients with colorectal cancer. Proc Am Soc Clin Oncol 14:167, 1995 (abstr)
18. Houghton PJ, Cheshire PJ, Hallman II JD, et al: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393-403, 1995
19. Hochster H, Liebes L, Zeleniuch-Jacquotte A, et al: Progressive cleavable complex (CC) formation with 21-day topotecan infusion: A phase I/pharmacodynamic study. Proc Am Soc Clin Oncol 14:463, 1995 (abstr)